26 Result(s)
-
Chapter
MCDA for Resource Allocation at a Local Level: An Application in the UK
Resource allocation at a local level involves making difficult decisions about investment and, particularly in a time of economic stringency, about disinvestment. These complex decisions are influenced by a nu...
-
Chapter
Incorporating Preferences and Priorities into MCDA: Selecting an Appropriate Scoring and Weighting Technique
A key component of many multi-criteria decision analyses (MCDAs) is the elicitation of stakeholder preferences in the form or scores and weights. A challenge to the MCDA practitioner is that there is little gu...
-
Article
Olaparib for Maintenance Treatment of BRCA 1 or 2 Mutated, Relapsed, Platinum-Sensitive Ovarian, Fallopian Tube and Peritoneal Cancer in People Whose Relapsed Disease has Responded to Platinum-Based Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
As part of its Single Technology Appraisal process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer of olaparib (AstraZeneca) to submit evidence on the clinical and cost e...
-
Article
Open AccessThe RAPID-CTCA trial (Rapid Assessment of Potential Ischaemic Heart Disease with CTCA) — a multicentre parallel-group randomised trial to compare early computerised tomography coronary angiography versus standard care in patients presenting with suspected or confirmed acute coronary syndrome: study protocol for a randomised controlled trial
Emergency department attendances with chest pain requiring assessment for acute coronary syndrome (ACS) are a major global health issue. Standard assessment includes history, examination, electrocardiogram (EC...
-
Article
Sipuleucel-T for the Treatment of Metastatic Hormone-Relapsed Prostate Cancer: A NICE Single Technology Appraisal; An Evidence Review Group Perspective
The National Institute for Health and Care Excellence (NICE) invited Dendreon, the company manufacturing sipuleucel-T, to submit evidence for the clinical and cost effectiveness of sipuleucel-T for asymptomati...
-
Article
Resource Modelling: The Missing Piece of the HTA Jigsaw?
Within health technology assessment (HTA), cost-effectiveness analysis and budget impact analyses have been broadly accepted as important components of decision making. However, whilst they address efficiency...
